Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-13	€1.125	-0.44%	8,000
26-08-12	€1.130	+1.80%	1,000
26-08-11	€1.110	-0.45%	7,000
26-08-10	€1.115	-0.45%	13,000
26-08-07	€1.120	-3.03%	145,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Real-time Borsa Italiana 04:45:06 2026-08-13 am EDT			5-day change	1st Jan Change
1.125 ^EUR	-0.44%		-2.60%	-23.47%

Jul. 06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
Jun. 29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN

Market Cap	9.63M 11.11M 9.02M 8.23M 15.47M 1.06B 15.71M 106M 41.47M 531M 41.72M 40.82M 1.77B	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	9.92M 11.45M 9.3M 8.48M 15.94M 1.09B 16.19M 109M 42.74M 547M 43M 42.07M 1.82B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	33.31%	Yield 2024 *	-	Yield 2025	-

Jul. 06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
Jun. 29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
Jun. 22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
Jun. 19	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
Jun. 15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
Jun. 04	Equities trend higher; banks lead gains on the MIB	AN
May. 22	European markets rebound; STM and Stellantis lead gains	AN
May. 21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
May. 21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
May. 21	European markets set for lower open; focus on manufacturing PMIs	AN
Apr. 20	Brent rebounds; futures signal risk-off sentiment	AN
Apr. 17	Greenlight on Hormuz sparks global equity rally	AN
Apr. 12	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Apr. 09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
25-10-21	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
25-08-29	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
25-06-04	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
25-05-19	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Stock

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Jul. 06	Laboratorio Erfo prosegue buyback e rileva 15.000 azioni proprie
Jun. 29	Laboratorio Farmaceutico Erfo rileva 14.000 azioni proprie
Jun. 22	Erfo prosegue coi buyback e riacquista 28.000 azioni
Jun. 15	Laboratorio Farmaceutico Erfo acquista 15.000 azioni proprie
Jun. 04	Borse rialziste; bene i bancari sul MIB

1 day	-0.44%
1 week	-2.60%
Current month	-1.32%
1 month	-9.64%
6 months	-19.06%
Current year	-23.47%

1 week	1.08	1.14
1 month	1.08	1.24
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	2012-12-31
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	2012-12-31
Flavio Corpina BRD	Director/Board Member	47	2016-12-31
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/16/25	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
12/16/25	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
6/29/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	-0.44%	-2.60%	-7.02%	+10.84%	11.11M
ELI LILLY AND COMPANY	+0.43%	+4.31%	+90.84%	+130.99%	1,088B
JOHNSON & JOHNSON	+0.41%	+1.27%	+50.98%	+50.05%	629B
ABBVIE INC.	-0.53%	+1.04%	+25.23%	+63.46%	440B
ROCHE HOLDING AG	-0.21%	+0.03%	+46.10%	+37.74%	359B
NOVARTIS AG	-0.02%	-0.96%	+27.13%	+36.36%	291B
ASTRAZENECA PLC	-0.27%	-1.70%	+1.79%	+4.81%	245B
AMGEN INC.	+0.45%	+2.05%	+46.04%	+58.54%	225B
NOVO NORDISK A/S	-0.76%	+1.19%	-8.84%	-52.03%	204B
GILEAD SCIENCES, INC.	+0.07%	+3.12%	+13.21%	+69.84%	168B
Average	-0.20%	+1.01%	+28.54%	+41.06%	364.92B
Weighted average by Cap.	-0.26%	+1.93%	+48.67%	+66.17%

	2024	2025
Net sales	6.03M 6.96M 5.65M 5.16M 9.69M 664M 9.84M 66.48M 25.99M 333M 26.14M 25.57M 1.11B	9.73M 11.23M 9.12M 8.32M 15.64M 1.07B 15.88M 107M 41.92M 536M 42.17M 41.26M 1.79B
Net income	353K 407K 331K 302K 567K 38.84M 576K 3.89M 1.52M 19.45M 1.53M 1.5M 64.85M	737K 851K 691K 630K 1.18M 81.13M 1.2M 8.12M 3.17M 40.62M 3.19M 3.12M 135M
Net Debt	5.77K 6.66K 5.4K 4.93K 9.27K 635K 9.41K 63.55K 24.84K 318K 24.99K 24.45K 1.06M	295K 341K 277K 252K 475K 32.52M 482K 3.26M 1.27M 16.28M 1.28M 1.25M 54.3M